Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
12.40
-0.13 (-1.04%)
At close: Sep 5, 2025, 4:00 PM
12.40
0.00 (0.00%)
After-hours: Sep 5, 2025, 5:22 PM EDT
Company Description
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs.
It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases.
It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Aurinia Pharmaceuticals Inc.
| Country | Canada |
| Founded | 1993 |
| IPO Date | Jan 26, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Peter Greenleaf |
Contact Details
Address: #140, 14315 – 118 Avenue Edmonton, AB T5L 4S6 Canada | |
| Phone | 250 744 2487 |
| Website | auriniapharma.com |
Stock Details
| Ticker Symbol | AUPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001600620 |
| CUSIP Number | 05156V102 |
| ISIN Number | CA05156V1022 |
| Employer ID | 98-1231763 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter S. Greenleaf M.B.A. | President, Chief Executive Officer and Director |
| Joseph M. Miller CPA | Chief Financial Officer |
| Matthew Maxwell Donley M.B.A. | Chief Operations Officer |
| Stephen P. Robertson | Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer |
| Dr. Gregory F. Keenan M.D. | Chief Medical Officer |
| Andrea Levin Christopher | Executive Director of Corporate Communications and Investor Relations |
| Dr. Premchandran Ramiya Ph.D. | Senior Vice President of Manufacturing and Supply Chain |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | SCHEDULE 13D/A | Filing |
| Jul 31, 2025 | 10-Q | Quarterly Report |
| Jul 31, 2025 | 8-K | Current Report |
| Jun 30, 2025 | 8-K | Current Report |
| May 16, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 15, 2025 | 8-K | Current Report |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | 8-K | Current Report |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |